Your browser is no longer supported. Please, upgrade your browser.
Settings
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-27.89 Insider Own0.28% Shs Outstand328.31M Perf Week-2.91%
Market Cap61.78B Forward P/E11.12 EPS next Y16.93 Insider Trans0.00% Shs Float327.36M Perf Month-1.74%
Income-9268.00M PEG- EPS next Q4.57 Inst Own93.60% Short Float4.45% Perf Quarter7.54%
Sales15.82B P/S3.91 EPS this Y24.90% Inst Trans1.86% Short Ratio6.33 Perf Half Y17.58%
Book/sh178.28 P/B1.06 EPS next Y0.15% ROA-9.50% Target Price189.71 Perf Year19.43%
Cash/sh13.88 P/C13.56 EPS next 5Y3.40% ROE-15.10% 52W Range114.27 - 194.61 Perf YTD-1.56%
Dividend2.96 P/FCF10.74 EPS past 5Y-36.00% ROI-4.80% 52W High-3.30% Beta1.70
Dividend %1.57% Quick Ratio0.90 Sales past 5Y43.40% Gross Margin85.00% 52W Low64.69% ATR1.59
Employees16900 Current Ratio1.00 Sales Q/Q3.60% Oper. Margin-60.30% RSI (14)40.01 Volatility0.83% 0.75%
OptionableYes Debt/Eq0.39 EPS Q/Q- Profit Margin-58.50% Rel Volume1.50 Prev Close190.60
ShortableYes LT Debt/Eq0.32 EarningsJan 28 BMO Payout- Avg Volume2.30M Price188.19
Recom2.80 SMA20-1.89% SMA50-0.07% SMA20015.15% Volume3,447,097 Change-1.26%
Jan-22-20Downgrade Wells Fargo Overweight → Equal Weight $198
Nov-19-19Downgrade UBS Buy → Neutral $189 → $203
Aug-07-19Downgrade Guggenheim Buy → Neutral
Jul-18-19Downgrade SVB Leerink Outperform → Mkt Perform
Jul-16-19Downgrade Bernstein Outperform → Mkt Perform
Jun-11-19Initiated Barclays Underweight $133
May-28-19Initiated Goldman Neutral
Apr-15-19Initiated Jefferies Hold
Mar-20-19Initiated SunTrust Buy $178
Jan-31-19Downgrade Credit Suisse Outperform → Neutral
Jan-30-19Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-30-19Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-09-18Resumed Guggenheim Buy
Apr-24-18Resumed Citigroup Buy $200
Apr-23-18Resumed Evercore ISI Outperform
Apr-17-18Initiated Stifel Hold $192
Feb-23-18Initiated SunTrust Buy $200
Feb-07-18Reiterated Leerink Partners Outperform $237 → $242
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-27-20 04:26AM  AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys Reuters
02:06AM  Allergan Sells Drugs to Nestle and AstraZeneca Ahead of AbbVie Tie-Up TheStreet.com
01:29AM  Nestle buys Allergan business to expand in medical nutrition Reuters
01:15AM  AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep PR Newswire
Jan-24-20 10:30AM  Form 8.3 - Allergan plc Business Wire
09:51AM  FORM 8.3 - ALLERGAN PLC - AMENDMENT Business Wire
07:17AM  Form 8.3 - Allergan plc Business Wire
Jan-22-20 10:07AM  FORM 8.3 - ALLERGAN PLC Business Wire
Jan-20-20 10:01AM  Form 8.3 - ALLERGAN PLC Business Wire
Jan-17-20 09:30AM  Form 8.3 - Allergan plc - Amendment Business Wire
08:06AM  FORM 8.3 - ALLERGAN PLC Business Wire
07:30AM  SkinMedica® Launches New Instant Bright Eye Cream For Immediate, Visible Results PR Newswire
Jan-16-20 09:50AM  Is Allergan (AGN) a Great Stock for Value Investors? Zacks
09:01AM  J&J Seeks Label Expansion for Spravato Nasal Spray in EU Zacks
08:20AM  Form 8.3 - ALLERGAN PLC - AMENDMENT Business Wire
07:38AM  Form 8.3 - Allergan plc Business Wire
07:30AM  Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living PR Newswire
Jan-15-20 08:00AM  3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio Zacks
06:25AM  Form 8.3 - Allergan plc Business Wire
Jan-14-20 01:01PM  AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc. Moody's
10:22AM  Form 8.3 - Allergan plc - Amendment Business Wire
09:05AM  Form 8.3 - ALLERGAN PLC Business Wire
Jan-13-20 05:03PM  Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I Zacks
09:11AM  Endo Up on Opioid Abuse Settlement Agreement With Oklahoma Zacks
06:03AM  Form 8.3 - ALLERGAN PLC Business Wire
Jan-10-20 09:46AM  Form 8.3 - Allergan plc - Amendment Business Wire
09:11AM  Form 8.3 - Allergan plc - Amendment Business Wire
07:18AM  Form 8.3 - ALLERGAN PLC - Amendment Business Wire
Jan-09-20 12:13PM  Form 8.3 - ALLERGAN PLC Business Wire
08:39AM  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results Benzinga
Jan-08-20 03:38PM  AbbVie to separate Botox in new aesthetics unit; Brent Saunders won't have role MarketWatch
Jan-06-20 09:45AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
08:23AM  Amgen Stock Up in a Year on Pipeline & Biosimilar Progress Zacks
08:00AM  Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
07:00AM  Warner Chilcott and Watson Resolve Antitrust Class Action Litigation with Direct and Indirect Purchasers of Loestrin 24 Fe and Minastrin 24 Fe PR Newswire
Jan-03-20 06:50PM  3 Stocks with Solid Entry Points to Consider for 2020 Zacks
11:48AM  Novartis, Merck and Allergan join those raising U.S. drug prices for 2020 Reuters
10:04AM  Aerie's (AERI) Application for Roclanda Accepted in Europe Zacks
09:00AM  AbbVie Stock Is Poised To Become A Top Pharma But Should You Buy It? Investor's Business Daily
Jan-02-20 09:35AM  5 Reasons Why Ironwood Stock Should Be in Your Portfolio Zacks
Dec-31-19 09:26AM  Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study Zacks
Dec-30-19 08:57AM  The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck Zacks
Dec-27-19 04:15PM  3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020 Zacks
11:34AM  5 Companies Hit 52-Week Highs GuruFocus.com
Dec-26-19 06:34AM  Bull of the Day: InMode (INMD) Zacks
Dec-24-19 11:44AM  Hedge Fund Consensus Stocks vs. Allergan plc (AGN) In 2019 Insider Monkey
10:12AM  Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy Zacks
Dec-23-19 03:13PM  Allergan Receives U.S. FDA Approval for UBRELVY for the Acute Treatment of Migraine with or without Aura in Adults PR Newswire
03:05PM  Allergan's migraine drug approved by FDA MarketWatch
02:47PM  Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
Dec-19-19 04:44PM  Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration PR Newswire
08:37AM  Allergan Foundation Giving Reaches $95 Million Since Inception PR Newswire
Dec-17-19 05:05PM  Heres how Wall Streets favorite stock picks turned out in 2019 MarketWatch
Dec-16-19 02:55PM  Will Allergan's Combination with AbbVie Give Botox Sales a Facelift? TheStreet.com
07:00AM  BOTOX® (onabotulinumtoxinA) Celebrates 30 Years of Endless Innovation PR Newswire
Dec-13-19 12:19PM  Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020 Investor's Business Daily
11:44AM  5 Cheap Dividend Stocks With High Yields And Annual Increases InvestorPlace
06:00AM  Walgreens, AbbVie, and 3 Other Dividend Aristocrat Stocks That Have Lagged the Market This Year Barrons.com
Dec-12-19 02:00PM  AbbVie's 2019 Points to the End of the Efficient Market Thesis - Cramer TheStreet.com
Dec-11-19 08:12AM  Exicure shares rise on immuno-oncology trial MarketWatch
Dec-10-19 10:10AM  Biotech ETFs Hit New Highs on Deal Activities Zacks
Dec-09-19 05:23PM  Drug manufacturers have spent a record $342 billion on M&A in 2019 MarketWatch
Dec-05-19 04:54PM  John Paulson's Top 5 Buys in the 3rd Quarter GuruFocus.com
11:31AM  Allergan (AGN) Up 4.5% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-19 05:26PM  Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine PR Newswire
10:10AM  AstraZeneca Sells Schizophrenia Drug Rights in US and Canada Zacks
05:00AM  Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018 American City Business Journals
Nov-29-19 02:00PM  Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019 PR Newswire
12:36PM  Private Capital Exits Allergan, Universal Health Services GuruFocus.com
08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-28-19 07:00AM  The 3 Worst-Performing Health Care Stocks of 2019 So Far Barrons.com
Nov-27-19 11:10PM  Here is the 23rd Most Popular Stock Among 752 Hedge Funds Insider Monkey
07:06PM  3 Stocks for Value Investors to Buy as Market Reaches New High Zacks
Nov-26-19 06:06PM  National Consumer Rights Law Firm FeganScott Files Second, Expanded Class-Action Lawsuit Against Allergan TEST Business Wire Releases
06:06PM  National Consumer Rights Law Firm FeganScott Files Second, Expanded Class-Action Lawsuit Against Allergan Business Wire
Nov-20-19 09:30AM  Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
Nov-19-19 11:39AM  Mason Hawkins' Southeastern Buys 1, Sells 2 in 3rd Quarter GuruFocus.com
11:22AM  Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association PR Newswire
09:31AM  Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex Zacks
Nov-18-19 05:19PM  Daniel Loeb's Top 5 Buys in the 3rd Quarter GuruFocus.com
02:25PM  Mason Hawkins Sells Alphabet, General Electric GuruFocus.com
07:30AM  Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day PR Newswire
Nov-17-19 06:41AM  Hedge Funds Open Kimono: Here Are Their Top 5 Large-Cap Stock Picks Insider Monkey
Nov-14-19 06:24PM  Seth Klarman Exits Allergan, Buys 3 New Positions in 3rd Quarter GuruFocus.com
10:05AM  Allergan, Exicure Strike Collaboration Agreement For Hair Loss Disorder Drugs Benzinga
08:28AM  Exicures shares up on Allergan partnership MarketWatch
06:00AM  Beware of Runs on Bond Funds Barrons.com
05:01AM  AbbVie Sold $30 Billion in Bonds, and Two More Numbers to Know Barrons.com
Nov-13-19 01:00PM  Biohaven Readies for David Versus Goliath Battle with Allergan Bloomberg
12:03PM  AbbVie Takes on Debt to Buy Allergan GuruFocus.com
10:46AM  AbbVies $30 Billion Bond Sale Was Wall Streets Biggest This Year Barrons.com
10:00AM  Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal Zacks
09:35AM  The Zacks Analyst Blog Highlights: Booking, Allergan, Honda Motor, Infosys and Activision Blizzard Zacks
Nov-12-19 05:12PM  AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition Bloomberg
03:24PM  How KKR Could Pull Off a Walgreens Takeover Barrons.com
02:08PM  Top Stock Reports for Booking Holdings, Allergan & Honda Motor Co. Zacks
06:46AM  AbbVie sells $30bn of bonds to finance Allergan takeover Financial Times
05:00AM  AbbVie Eyes Up to $28 Billion Bond Sale to Finance Allergan Deal: Report TheStreet.com
Nov-11-19 05:13PM  Allergan CEO on Innovation and Blockbuster Biopharmaceuticals Bloomberg
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has a collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and gene therapy research collaboration with The National Institute for Bioprocessing Research and Training. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUNDERS BRENT LChairman, President and CEOMar 07Buy143.671,760252,858170,666Mar 07 03:19 PM